The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Real-world evidence of outcomes of heavily pretreated patients with myeloma treated with talquetamab
Amrita Krishnan, MD, City of Hope, Duarte, CA, provides an insight into the real-world evidence on the efficacy and safety of talquetamab in a heavily pretreated population with multiple myeloma (MM), noting that response rates and side effect profiles are consistent with clinical trial data. Dr Krishnan briefly comments on the importance of understanding the side effect profiles of different bispecific antibodies and highlights the unique toxicities of talquetamab, including dysgeusia, skin toxicity, and nail toxicity. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So this was an abstract that was done through the International Myeloma Working Group Consortium. Multiple centers looking at retrospective data of real-world patients treated with talquetamab and it really mirrored the clinical trial experience in terms of response rates being very high in the 60 to 70 percent range and again patients with a median of five to six prior lines of therapy...
So this was an abstract that was done through the International Myeloma Working Group Consortium. Multiple centers looking at retrospective data of real-world patients treated with talquetamab and it really mirrored the clinical trial experience in terms of response rates being very high in the 60 to 70 percent range and again patients with a median of five to six prior lines of therapy. Side effect profiles also being very consistent in terms of dygeusia being probably the leading side effect, infectious profile also being very similar to what we saw in the clinical trial population. So I think with this large body of real-world evidence now, it makes us much more comfortable in terms of use of talquetamab in the setting now that it’s FDA approved.
So understanding toxicity and supportive care is key to bispecifics because obviously we want to maintain patients on therapy, they do have certain unique side effect profiles. So what’s in common is cytokine release, generally low grade, easily manageable, needs to be recognized and treated early. Infection profiles tend to differ. So GPRC-directed bispecifics have a much lower infection profile than BCMA-directed bispecifics. Nonetheless, again, supportive care is important in terms of PJP prophylaxis, zoster prophylaxis, the use of IVIg. But talquetamab does have a few unique toxicities in terms of dygeusia, skin and nail toxicity that are again manageable with supportive care as well as dose and schedule adjustments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
